CHEST Physician
-
Using consumer sleep trackers in clinical practice
Consumer sleep technologies are offering new ways to monitor sleep. Clinicians need to be prepared to discuss this data, clarify limitations, and interpret findings with patients.
-
Is there a ‘best’ vasopressor and inotrope combination for shock with RV failure?
Review unique pathophysiologic challenges of RV failure in shock and comparative data on vasopressors and inotropes.
-
The respiratory toll of traffic pollution in obstructive lung disease and ILD
Traffic-related air pollution reduces lung function and worsens cases of COPD and ILD. Pulmonologists should assess patient exposure and advise on mitigation strategies.
-
A profession in motion: Shifting numbers and growing roles in respiratory therapy
Although the RT profession is navigating some challenges, the positive job outlook, increasing number of programs, and growing acceptance of APRTs represent a promising path forward.
-
Nerandomilast opens the door for potential monotherapy, add-on therapy for pulmonary fibrosis
Positive results from the FIBRONEER trials of nerandomilast in IPF and PPF have sent the phosphodiesterase 4B inhibitor to the FDA for marketing approval. If approved, nerandomilast would be the first new antifibrotic agent for ILD in more than a decade.
-
Prevention of COPD exacerbations with an eosinophilic endotype
With the recent US approval of the IL-5-directed monoclonal antibody mepolizumab as an add-on therapy for patients with COPD, the era of COPD biologics is undeniably here.
-
Moderate to severe OSA increases risk of severe COVID-19
According to critical care specialist Lina Miyakawa, MD, FCCP, the findings are a reminder that OSA “is not just a sleep disorder but a systemic condition with meaningful public health implications.”
-
Shock resuscitation: Making the first 30 minutes count
Physician-educators share their approach to teaching shock recognition and management core skills to residents at the bedside.
-
Optimizing lung transplant care
In the evolving landscape of transplant medicine, APPs are proving to be indispensable through their clinical expertise, consistency, and adaptability across care settings.
-
Beyond the pump: Clinical and psychosocial dimensions of LVAD therapy
Advanced HFrEF carries high mortality, but LVAD therapy can improve survival, heart function, and quality of life.
